Nanosys

Nanomal, a European Union-funded public-private consortium developing a handheld device for rapid, point-of-care molecular diagnosis of malaria and drug resistance, said this week that the instrument is a year ahead of schedule and will be ready for field testing later this year.

QuantumDx is heading a UK-based public-private partnership to develop a chip-based molecular profiling tool for diagnosing and staging cancer, and potentially guiding oncology treatments.

By Ben Butkus